HASAN ÇAĞRI YILDIRIM

1. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.

Acta Medica , cilt.56, sa.3, ss.186-198, 2025 (TRDizin)

2. Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines

KUŞ F., Chalabiyev E., YILDIRIM H. Ç., Koc Kus I., ŞİRVAN F., DİZDAR Ö., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.35, sa.1, ss.68-74, 2025 (SCI-Expanded, Scopus, TRDizin)

3. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.

JOURNAL OF CLINICAL MEDICINE , sa.6, 2025 (SCI-Expanded, Scopus)

4. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.

BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

5. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.

JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded, Scopus)

6. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group

AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., AHMED M. A., et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , cilt.34, ss.1359-1365, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.

BIOMOLECULES AND BIOMEDICINE , cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus)

8. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.

MEDICINE , cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)

9. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.

International Journal of Clinical Oncology , cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)

10. Acute heart failure following pazopanib treatment: a literature review featuring two case reports

KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.

Anti-Cancer Drugs , cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded, Scopus)

11. Sirolimus experience in adult patients with vascular malformations

AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.

Vascular , 2024 (SCI-Expanded, Scopus)

12. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

YILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sanci P. C., Guliyev M., et al.

Journal of Chemotherapy , 2024 (SCI-Expanded, Scopus)

13. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.

INTEGRATIVE CANCER THERAPIES , cilt.23, 2024 (SCI-Expanded, Scopus)

14. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology

YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.

Irish Journal of Medical Science , cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

15. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Avcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., et al.

Journal of Geriatric Oncology , cilt.14, sa.8, 2023 (SCI-Expanded, Scopus)

16. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer

YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., et al.

Anti-cancer drugs , cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded, Scopus)

17. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.

Journal of Immunotherapy and Precision Oncology , cilt.6, sa.4, ss.170-176, 2023 (Scopus)

18. Advances in the Early Detection of Hepatobiliary Cancers

YILDIRIM H. Ç., KAVGACI G., Chalabiyev E., DİZDAR Ö.

Cancers , cilt.15, sa.15, 2023 (SCI-Expanded, Scopus)

19. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)

20. SMART syndrome: a case report

Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.

ACTA NEUROLOGICA BELGICA , cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)

21. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.

Medicine (United States) , cilt.102, sa.18, 2023 (SCI-Expanded, Scopus)

22. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma

GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.

European Archives of Oto-Rhino-Laryngology , cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus)

23. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.

Biomarkers in Medicine , cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)

24. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)

25. Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey

Kus C., Kus M. M., Keten H. S., Ucer H., Guvenc N., KUŞ F., et al.

Children , cilt.10, sa.2, 2023 (SCI-Expanded, Scopus)

26. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

GÜRSOY P., TATLI A. M., Erdem D., GÖKER E., Celik E., Demirci N. S., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.2, ss.865-875, 2023 (SCI-Expanded, Scopus)

27. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

28. Leptomeningeal metastasis in primary uterine cervical cancer: a rare case and review of the literature

KAHVECİOĞLU A., Sari S. Y., YILDIRIM H. Ç., ARIK Z., GÜLTEKİN M., YILDIZ F.

Corrosion Science and Technology , cilt.19, sa.3, ss.184-189, 2023 (ESCI, Scopus)

29. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.

Journal of Oncological Science , cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)

30. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)

31. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.

BREAST , cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)

32. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , cilt.15, sa.4, ss.307-310, 2022 (ESCI, Scopus)

33. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)

34. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)

35. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study

Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.4, 2022 (SCI-Expanded, Scopus)

36. HER2-low breast cancer could be associated with an increased risk of brain metastasis

GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin) Sürdürülebilir Kalkınma

38. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)

39. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., et al.

Turkish Journal of Medical Sciences , cilt.52, sa.4, ss.1022-1032, 2022 (SCI-Expanded, Scopus, TRDizin)

40. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)

41. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.168, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

42. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)

43. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

44. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

48. Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery

Akagunduz B., AKIN TELLİ T., SEZGİN GÖKSU S., YILDIRIM H. Ç., Ozer M., Aydin S. G., et al.

CUREUS , cilt.13, sa.2, 2021 (ESCI)

49. Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group

Akagunduz B., AKIN TELLİ T., YILDIRIM H. Ç., SEZGİN GÖKSU S., DEMİR N., Hafizoglu E., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.31, sa.2, ss.92-98, 2021 (SCI-Expanded, Scopus, TRDizin)

50. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19

GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.

FRONTIERS IN ONCOLOGY , cilt.10, 2020 (SCI-Expanded, Scopus)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim